EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Indaptus Therapeutics's enterprise value is $4.83 Mil.
Indaptus Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.38 Mil. Therefore, Indaptus Therapeutics's EV-to-EBITDA for today is -0.29.
The historical rank and industry rank for Indaptus Therapeutics's EV-to-EBITDA or its related term are showing as below:
INDP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.52 Med: 0 Max: 4.86
Current: -0.29
During the past 4 years, the highest EV-to-EBITDA of Indaptus Therapeutics was 4.86. The lowest was -93.52. And the median was 0.00.
INDP's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.1
vs INDP: -0.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Indaptus Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Indaptus Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Indaptus Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Indaptus Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's EV-to-EBITDA falls into.
Indaptus Therapeutics's current Enterprise Value is $4.83 Mil.
Indaptus Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Indaptus Therapeutics's PE Ratio for today is calculated as:
Indaptus Therapeutics's share price for today is $2.11.
Indaptus Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Indaptus Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your 